AU2022420913A1 - Pharmaceutical composition comprising salbutamol - Google Patents

Pharmaceutical composition comprising salbutamol Download PDF

Info

Publication number
AU2022420913A1
AU2022420913A1 AU2022420913A AU2022420913A AU2022420913A1 AU 2022420913 A1 AU2022420913 A1 AU 2022420913A1 AU 2022420913 A AU2022420913 A AU 2022420913A AU 2022420913 A AU2022420913 A AU 2022420913A AU 2022420913 A1 AU2022420913 A1 AU 2022420913A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
mass
salbutamol
active ingredient
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022420913A
Other languages
English (en)
Inventor
Isabelle PEYRON
Irene ROSSI
Ségolène SARRAILH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptar France SAS
Original Assignee
Aptar France SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptar France SAS filed Critical Aptar France SAS
Publication of AU2022420913A1 publication Critical patent/AU2022420913A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2022420913A 2021-12-20 2022-12-19 Pharmaceutical composition comprising salbutamol Pending AU2022420913A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FRFR2113999 2021-12-20
FR2113999A FR3130554B1 (fr) 2021-12-20 2021-12-20 Composition pharmaceutique comprenant du salbutamol
PCT/FR2022/052421 WO2023118717A1 (fr) 2021-12-20 2022-12-19 Composition pharmaceutique comprenant du salbutamol

Publications (1)

Publication Number Publication Date
AU2022420913A1 true AU2022420913A1 (en) 2024-05-23

Family

ID=80595325

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022420913A Pending AU2022420913A1 (en) 2021-12-20 2022-12-19 Pharmaceutical composition comprising salbutamol

Country Status (9)

Country Link
US (1) US20250041244A1 (https=)
EP (1) EP4452227B1 (https=)
JP (1) JP2024546201A (https=)
CN (1) CN118510492A (https=)
AU (1) AU2022420913A1 (https=)
CA (1) CA3238932A1 (https=)
FR (1) FR3130554B1 (https=)
MX (1) MX2024006942A (https=)
WO (1) WO2023118717A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250281404A1 (en) * 2024-03-07 2025-09-11 Recipharm Laboratories, Inc. Composition for use in pressurised dispensing container

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007020204A2 (en) * 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
GB2573297A (en) * 2018-04-30 2019-11-06 Mexichem Fluor Sa De Cv Pharmaceutical composition

Also Published As

Publication number Publication date
CA3238932A1 (fr) 2023-06-29
EP4452227C0 (fr) 2025-11-26
MX2024006942A (es) 2024-09-10
EP4452227B1 (fr) 2025-11-26
JP2024546201A (ja) 2024-12-18
US20250041244A1 (en) 2025-02-06
CN118510492A (zh) 2024-08-16
FR3130554B1 (fr) 2024-10-18
FR3130554A1 (fr) 2023-06-23
EP4452227A1 (fr) 2024-10-30
WO2023118717A1 (fr) 2023-06-29

Similar Documents

Publication Publication Date Title
JP7228726B2 (ja) 医薬組成物
EP1480616B1 (en) Aerosol formulations of diisobutyryl apomorphine
JP2010215637A (ja) β２−アゴニストの溶液を含有する加圧式定量用量吸入器
ITMI20000312A1 (it) Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva
PL193721B1 (pl) Kompozycja do stosowania w inhalatorze aerozolowym, sposób napełniania inhalatora tą kompozycją oraz zastosowanie składnika niskolotnego
CN108289842B (zh) 药物组合物
CN112040930A (zh) 包括沙丁胺醇的药物组合物
US20030190289A1 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
DK2501363T3 (en) inhalable
JP7828949B2 (ja) 吸入投与のための併用療法
EP1715849A1 (en) Stable pharmaceutical solution formulation for pressurized metered dose inhalers
US20250041244A1 (en) Pharmaceutical composition comprising salbutamol
TWI449523B (zh) 福莫特羅（ｆｏｒｍｏｔｅｒｏｌ）及二丙酸倍氯米松（ｂｅｃｌｏｍｅｔａｓｏｎｅ ｄｉｐｒｏｐｉｏｎａｔｅ）之醫藥噴霧劑配方
US20130104881A1 (en) Stabilized Metered Dose Inhaler
JP2005536538A (ja) 薬学的組成物
US20260000630A1 (en) Pharmaceutical composition comprising salbutamol
US12383516B1 (en) Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent
US20070025920A1 (en) Stable Pharmaceutical Solution Formulations for Pressurized Metered Dose Inhalers
KR20060136446A (ko) 압축화 계량된 도스흡입용 안정된 약제용액 제제
JP2025137301A (ja) 加圧分配容器における使用のための組成物
MXPA06009584A (en) Stable pharmaceutical solution formulations for pressurized metered dose inhalers